Wemade Co., Ltd. Announces Pre-Registration for MIR 4, an Open World K-Fantasy MMORPG
29.7.2021 06:00:00 EEST | Business Wire | Press release
“From my battle to our war.” MIR 4, the unique open world K-Fantasy MMORPG, opens for global pre-registration on Thursday, 29 July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006129/en/
Wemade 's MIR 4, the unique open world K-Fantasy MMORPG, opens for global pre-registration on Thursday, 29 July. Pre-registration will be available on MIR 4’s official website, the Google Play Store and the Apple App Store. Pre-registered users will enjoy various in-game items on launch. The game beautifully portrays the mystical and elegant life of the Orient, offering a truly singular experience for MMORPG players across the world. The global version is upgraded from the Korean in that it has adopted blockchain technology. The digital assets in MIR 4 can be made NFT or FT in order to buy, sell or trade for profit. The global release will be available in more than 170 countries on both mobile and PC. (Graphic: Business Wire)
The game beautifully portrays the mystical and elegant life of the Orient, offering a truly singular experience for MMORPG players across the world.
The game is designed to offer players the chance to choose their own paths without limitation. This might involve becoming a merchant, trading and selling materials to gain wealth, creating the most powerful clan in the world rising in power or simply venturing into the unknown with friends to tell a grand tale – the choice is entirely up to the player.
With no set guidelines defining success in the game, players instead focus on four fundamental principles: social, economic, political and competitive, to focus on their characters’ needs and wants, thus creating a cycle of life in the game’s world.
MIR 4 was first released in South Korea in November 2020. On release, it quickly became the country’s most downloaded game. The global version is upgraded from the Korean in that it has adopted blockchain technology. The digital assets in MIR 4 can be made NFT or FT in order to buy, sell or trade for profit.
Pre-registration will be available on MIR 4’s official website, the Google Play Store and the Apple App Store. Pre-registered users will enjoy various in-game items on launch.
The global release will be available in more than 170 countries in 12 languages (Korean, English, Japanese, Chinese/Traditional, Chinese/Simplified, Thai, Indonesian, Vietnamese, German, Spanish, Portuguese and Russian) on both mobile and PC. MIR 4’s global CBT will be held for four days, between 5 and 8 August 2021.
Visit www.mir4global.com for more details on this highly anticipated MMORPG.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006129/en/
Contact information
Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee,
PR Manager
+82-2-3709-2553
yeonghyun@wemade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom